Literature DB >> 21547530

Downregulation of GABA(A) β subunits is transcriptionally controlled by Fmr1p.

Andrew Hong1, Aiying Zhang, Yang Ke, Abdeslem El Idrissi, Chang-Hui Shen.   

Abstract

Fragile X mental retardation syndrome is caused by the transcriptional silence of FMR1. Here, a quantitative PCR technique was used to examine the effect of Fmr1p on the expression of GABA(A) β subunits in different mouse brain regions. Our results demonstrated the reduction of GABA(A) β2 mRNA in all brain regions assessed, and the reduction of GABA(A) β3 mRNA in the cortex, suggesting that the expression of GABA(A) β subunits is transcriptionally regulated by Fmr1p. This finding may help to establish the link between the transcriptional profile of the GABAergic inhibitory system and the development of fragile X mental retardation syndrome.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21547530     DOI： 10.1007/s12031-011-9531-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN： 0895-8696            Impact factor:   3.444


  18 in total

Review 1.  Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond.

Authors:  Aaron W Grossman; Georgina M Aldridge; Ivan Jeanne Weiler; William T Greenough
Journal:  J Neurosci       Date:  2006-07-05       Impact factor: 6.167

2.  Disruption of interneuron development.

Authors:  Pat Levitt
Journal:  Epilepsia       Date:  2005       Impact factor: 5.864

3.  Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome.

Authors:  V Brown; P Jin; S Ceman; J C Darnell; W T O'Donnell; S A Tenenbaum; X Jin; Y Feng; K D Wilkinson; J D Keene; R B Darnell; S T Warren
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

4.  Fragile X mice develop sensory hyperreactivity to auditory stimuli.

Authors:  L Chen; M Toth
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 5.  An update on GABAA receptors.

Authors:  A K Mehta; M K Ticku
Journal:  Brain Res Brain Res Rev       Date:  1999-04

6.  Loss of the major GABA(A) receptor subtype in the brain is not lethal in mice.

Authors:  C Sur; K A Wafford; D S Reynolds; K L Hadingham; F Bromidge; A Macaulay; N Collinson; G O'Meara; O Howell; R Newman; J Myers; J R Atack; G R Dawson; R M McKernan; P J Whiting; T W Rosahl
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

7.  Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse.

Authors:  Abdeslem El Idrissi; Xiao-Hua Ding; Jason Scalia; Ekkhart Trenkner; W Ted Brown; Carl Dobkin
Journal:  Neurosci Lett       Date:  2004-12-23       Impact factor: 3.046

8.  The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation.

Authors:  D Devys; Y Lutz; N Rouyer; J P Bellocq; J L Mandel
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

9.  The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences.

Authors:  L Chen; S W Yun; J Seto; W Liu; M Toth
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 10.  Fragile X syndrome: from molecular genetics to therapy.

Authors:  C D'Hulst; R F Kooy
Journal:  J Med Genet       Date:  2009-09       Impact factor: 6.318
View more
  14 in total

Review 1.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 2.  Autism spectrum disorder and epilepsy: Disorders with a shared biology.

Authors:  Bo Hoon Lee; Tristram Smith; Alex R Paciorkowski
Journal:  Epilepsy Behav       Date:  2015-04-19       Impact factor: 2.937

3.  Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.

Authors:  Craig A Erickson; Logan K Wink; Balmiki Ray; Maureen C Early; Elizabeth Stiegelmeyer; Lauren Mathieu-Frasier; Vanessa Patrick; Debomoy K Lahiri; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2013-02-24       Impact factor: 4.530

4.  Neuregulin 1-induced AKT and ERK phosphorylation in patients with fragile X syndrome (FXS) and intellectual disability associated with obstetric complications.

Authors:  Tamás Kovács; Boglárka Bánsági; Oguz Kelemen; Szabolcs Kéri
Journal:  J Mol Neurosci       Date:  2014-02-23       Impact factor: 3.444

Review 5.  GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.

Authors:  S Hossein Fatemi; Timothy D Folsom
Journal:  Schizophr Res       Date:  2014-11-26       Impact factor: 4.939

6.  The effects of prenatal H1N1 infection at E16 on FMRP, glutamate, GABA, and reelin signaling systems in developing murine cerebellum.

Authors:  S Hossein Fatemi; Timothy D Folsom; Stephanie B Liesch; Rachel E Kneeland; Mahtab Karkhane Yousefi; Paul D Thuras
Journal:  J Neurosci Res       Date:  2016-10-13       Impact factor: 4.164

7.  Downregulation of GABAA receptor protein subunits α6, β2, δ, ε, γ2, θ, and ρ2 in superior frontal cortex of subjects with autism.

Authors:  S Hossein Fatemi; Teri J Reutiman; Timothy D Folsom; Oyvind G Rustan; Robert J Rooney; Paul D Thuras
Journal:  J Autism Dev Disord       Date:  2014-08

8.  Elevated levels of the vesicular monoamine transporter and a novel repetitive behavior in the Drosophila model of fragile X syndrome.

Authors:  John M Tauber; Phillip A Vanlandingham; Bing Zhang
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

Review 9.  Emerging pharmacologic treatment options for fragile X syndrome.

Authors:  Tori L Schaefer; Matthew H Davenport; Craig A Erickson
Journal:  Appl Clin Genet       Date:  2015-04-07

Review 10.  GABA system dysfunction in autism and related disorders: from synapse to symptoms.

Authors:  Suzanne Coghlan; Jamie Horder; Becky Inkster; M Andreina Mendez; Declan G Murphy; David J Nutt
Journal:  Neurosci Biobehav Rev       Date:  2012-07-25       Impact factor: 8.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.